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Abstract
Von Hippel-Lindau syndrome (VHL) is a rare disease of dominant inheritance that increases susceptibility to tumor
development, with a complete penetrance at the age of 60. In this report, we present the unprecedented case of a
VHL carrier who remains healthy at 72. Under the course of this study, it was discovered that this patient carries a
mutation for a second rare disease, Neuronal Ceroid Lipofuscinosis (NCL or CNL). We hypothesize that the CLN
mutation she carries offers a protective effect, preventing tumor development in the cells potentially suffering a
VHL second hit mutation. To test this hypothesis, we ran a series of molecular experiments and confirmed that cell
viability of primary endothelial cells decreases upon CLN5 silencing. Our results further elucidate the cell biology
implications of two rare diseases interacting.
Keywords: Von Hippel-Lindau (VHL), Neuronal Ceroid Lipofuscinosis type 5 (CLN5), Rare disease,
Hemangioblastoma (HB), Clear cell renal cell carcinoma (ccRCC), Endothelial cells (ECs)
Introduction
A rare disease affects, by definition, no more than 1 in
2000 individuals in the European Union [1], and less
than 200,000 total in the United States [2]. Although the
likelihood of having one rare disease is small, more than
7000 different types have been described, accounting for
30 million patients in Europe alone [3–5]. Despite the
increasing efforts to investigate rare diseases [6], little is
known about families, or patients carriers or suffering
more than one rare condition. The co-occurrence/segre-
gation of two independent diseases in consanguineous
and non-consanguineous families has been reported in
the past [7], but the molecular interaction between the
conditions has seldom been investigated. In this case
report we present a unique and, to the best of our know-
ledge, unprecedented combination of two rare diseases
segregating in a family, leading to an unexpected clinical
picture: a 72 year old woman carrying mutations in het-
erozygosis for both Neural Ceroid Lipofuscinosis (NCL
or CNL) and Von Hippel Lindau disease (VHL), with no
development of any pathology.
NCL are a group of neurodegenerative disorders of
recessive inheritance, with an incidence as high as 1 in
12,500 births [8]. Currently, fourteen genetically differing
forms have been described, corresponding to mutations
in different genes (CLN1 to CLN14), and they are all
characterized by loss of nerve cells and accumulation of
lipopigments within cells. This lysosomal lipid accumu-
lation is due to an inability to degrade lipids, and leads
to a neurological atrophy typical of the disease [9, 10].
The patient of this case report is NCL symptom-free, as
she is a carrier in heterozygosis for a CLN5 mutation.
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The other rare disease in play is VHL, a dominant auto-
somal disorder affecting 1 in every 36,000 births, charac-
terized by the susceptibility to a series of tumors, typically
hemangioblastomas (HB) of the Central Nervous System
(CNS) or retina, clear cell renal cell carcinomas (ccRCC)
and pheochromocytomas [11]. These develop after a
second hit mutation in VHL - a tumor suppressor gene -
causes the loss of functional VHL protein [12, 13]. Under
normoxic conditions, VHL protein recognizes and binds
the previously hydroxylated Hypoxia Inducible Factor
(HIF) to trigger its proteasomal degradation [14]. Tissues
suffering a stochastic VHL second hit mutation unfold a
lack of functional VHL protein, which induces a state of
pseudo-hypoxia, promoting tumor growth in these tissues
where cells have lost heterozygosis [15].
Despite VHL’s dominant inheritance and almost
complete penetrance at the age of 60 [16–18], the pa-
tient here presented has not shown any VHL symptoms
throughout her lifetime. However, her son inherited her
mutation and developed bilateral suprarenal tumors in
his thirties. Given the family history of two rare diseases,
this led us to think of a possible interaction between
NCL and VHL. In order to determine the possibility of
said interaction, we completed the genetic screening of
the patient and her relatives, and performed cellular and
molecular assays on primary and established cell lines.
The combination of our in vitro results and the clinical
data gathered from the studied family points towards a
protective effect by NCL in this patient regarding tumor
development: VHL cells that suffer a second hit muta-
tion in VHL cannot divide and progress to develop a
tumor, due to the lower viability caused by NCL haplo-
insufficiency, interfering in some way with the process of
tumorigenesis. These data show a unique counteracting
interaction resolving in a symptom-free patient.
Results and discussion
Background: family history
The family here presented came to our attention through
our collaboration with the Spanish VHL patient Alliance.
The first member of the family to be diagnosed with VHL
was subject E (Fig. 1), who presented with bilateral pheo-
chromocytomas at the age of 34. Upon genetic screening
of the immediate relatives, it was discovered that subject
A carried the same VHL mutation as subject E, and thus
had been maternally transmitted to him.
Intriguingly, subject A remains completely healthy at
the age of 72, despite her VHL mutation. Since her diag-
nosis, she undergoes annual examinations according to
the international follow-up protocol for VHL disease,
which includes direct and indirect ophthalmoscopy, MRI
of the CNS, abdominal MRI, diagnostic audiologic evalu-
ation and catecholamines tests. No clinical findings of
VHL have been found so far, constituting the only
known case to the best of our knowledge, of a VHL
patient lacking any of the disease symptoms. Taking a
closer look at the family’s history, we discovered that
patient A had two elder sons who died as teenagers, due
to a different rare disease: NCL. Upon learning this, we
realized that patient A is carrier of a CLN mutation, in
particular at the CLN5 gene.
Altogether, the family’s history suggests that her lack
of VHL symptoms can be based on a protective effect
that would prevent tumor development. At this point
our hypothesis was that this subject’s cells, in case of
suffering a VHL second hit mutation normally leading to
Fig. 1 Genetic pedigree of the family of interest showing information on their VHL and CLN5 genotypes and phenotypes (healthy, lipofuscinosis affected
or VHL). Circles represent females and squares represent males. The genotype and phenotype of each family member is indicated underneath. Subject A is
the subject of interest carrying a VHL mutation and not developing any tumors. Black arrow indicates first family member diagnosed with VHL
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tumor formation [11, 12], would be no longer viable due
to their CLN5 mutation, and thus would not progress
into tumor. The next experiments were designed to test
this hypothesis.
CLN5 silencing reduces cell viability in different primary
and established cell lines
Hemangioblastoma primary cell culture
To test our hypothesis, we started by silencing CLN5 in
HB cells from a VHL patient. These cells have already
suffered the second hit mutation and thus are VHL
(−/−), adequate to test how a CLN5 protein deficiency
might affect cell viability in them. In vitro cell cultures
showed a significantly reduced number of cells in the
CLN5 transfected groups, quantitatively supported by
cell counter measurements (Fig. 3a). Next, to assess if
apoptosis was promoting cell death in siCLN5 trans-
fected cells, Bax gene expression was quantified by
quantitative PCR (qPCR). Bax was chosen for its known
involvement in triggering apoptosis [19]. RT-qPCR ana-
lysis showed that CLN5 silencing was successful (Fig. 2a),
and that the levels of pro-apoptotic gene Bax appeared
significantly elevated in the partially CLN5 silenced
population (Fig. 2b). These results taken together make
us think that CLN5 deficient HB cells have a disadvan-
tage and do not expand at the rate control groups do,
since their viability is compromised.
786-O cell culture
As primary cultures of HB are sensitive to the process of
transfection by liposomes and were not expanding opti-
mally, we chose to continue with a more resistant VHL
(−/−) sample, the human ccRCC 786-O cell line. This
time, as a direct measure of cell viability, we quantified
ATP levels at different times after CLN5 gene silencing.
The reduction in cell viability was best seen at 48 h, with a
20% loss compared to control (Fig. 3b). The concordance
between the positive and negative controls shows that the
transfection reagent used for silencing (Lipofectamine)
does not have a significant effect on cell viability, and
therefore, the drop in cell viability in partially silenced
CLN5 cells is due only to the decrease of CLN5 transcript
levels.
ccRCC primary cell culture
Although we observed a decrease in cell viability upon
CLN5 depletion, this effect might be diluted by the high
replicative rate characteristic of a cell line. This is why
we chose a second VHL (−/−) primary cell culture,
different than HB (which was not expanding optimally):
primary ccRCC cells derived from the tumor of a VHL
patient. The previous results were successfully replicated
– again, a 20% decrease in cell viability is observed in
the siCLN5 group, 48 h after transfection (Fig. 3c). This
was visually apparent under the microscope; CLN5
silenced cells were less confluent than the control
groups (Fig. 3d).
CLN5 protein levels are decreased in endothelial cells
derived from VHL patients
Once we established that CLN5 silencing reduces cell
viability in VHL (−/−) tumor cells, we wondered whether
there is an interaction between CLN5 and VHL, both at
transcript and protein levels. We opted for qPCR meas-
urement of CLN5 gene expression, and Western blotting
to determine CLN5 protein levels in endothelial cells
(ECs) derived either from VHL patients or from healthy
donors. These primary culture cells called BOECs (Blood
Outgrowth Endothelial Cells) are heterozygous VHL
(+/−) in the VHL group, and VHL (+/+) in the control
group.
Both techniques indicated reduced levels of CLN5 in
the VHL group; qPCR showed a 0,6 fold reduction of
CLN5 expression in VHL versus the healthy control
(Fig. 4a), and a 20% reduction in CLN5 protein levels in
VHL (+/−) ECs, compared to control levels (Fig. 4b).
These results suggest a putative interaction between
CLN5 and VHL: lower levels of VHL protein seem to
Fig. 2 qPCR results in HB primary cells, 72 h after transfection with siCLN5 and siScrambled (siScl). Control group was left untreated, while siScl
serves as a negative control. The experiment was conducted in triplicates, representing the mean and showing the standard deviation as error
bars. a CLN5 expression; b Bax expression. Statistical significance is represented as *p < 0.05; **p < 0.01; and ***p < 0.001
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correlate with a decrease in CLN5 protein expression.
We think that there might be a direct interaction of both
proteins VHL and CLN5 in the cell, since both are part
of the cell degradative pathways - CLN5 is involved in
the lysosomal and VHL in the proteasomal degradation.
It is possible that a crosstalk among both pathways up to
a functioning threshold level may be necessary. Further
protein-interaction in vitro experiments would be neces-
sary to confirm this concept.
In summary, subject A, introduced in section 1 and
who is VHL (+/−) and CLN5 (+/−), would have a
roughly 50% deficiency in CLN5 protein due to her
heterozygous CLN5 mutation. In addition to this, and
according to our in vitro results, because of her VHL
mutation, her cells would be further reduced at CLN5
protein levels. As a result, despite the CLN5 heterozy-
gous condition, the real CLN5 levels would be below the
50% expected in a heterozygote. Upon a second hit in
VHL, the levels of CLN5 would fall even lower, below a
functional threshold, leading to a pseudolipofuscinosis
phenotype in cells suffering this second hit. This condi-
tion, highly toxic from a metabolic point of view, would
not enable cell proliferation and survival. Thus, the cells
suffering a VHL second hit mutation will not expand,
preventing tumor development. This hypothesis has
been supported by an observation made in our lab:
Fig. 3 a Cell count by Bio-Rad TC20 Automated Cell Counter. Primary HB cells were trypsinized 72 h after transfection with siCLN5 and siScl as
negative control. Cell viability was measured in 786-O cells (b) and ccRCC primary cells (c) 48 h after transduction by a luciferase assay, where
ATP levels are a direct correlation of cell viability. d ccRCC primary cell cultures under the microscope were photographed 72 h after transfection.
Control group was left untreated, while siScl serves as negative control. Every condition was replicated three times – the graphs show the
combined mean of these experiments, representing the obtained standard deviation in the error bars. Statistical significance is represented as
*p < 0.05; **p < 0.01; and ***p < 0.001
Fig. 4 a CLN5 expression levels as measured by qPCR. b CLN5 and actin protein expression by Western blot and further quantification. Statistical
significance is represented as *p < 0.05; **p < 0.01; and ***p < 0.001
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BOECs obtained from subject A are not susceptible to
VHL silencing. After siRNA VHL transfection, most of
the cells die, and the few remaining have no silenced
VHL, according to qPCR (data not shown). Overall, our
work suggests that a second hit mutation in VHL is
incompatible with a CLN5 heterozygosis cellular back-
ground. Protective effects of the kind have been previ-
ously described in VHL [20], and we propose that this is
a similar case, where one mutation suggests the patient
to a protection against the disease development.
Methods
Cell culture
CNS HB and ccRCC primary cultures from excess of
resected surgeries of VHL patients under informed consent
were isolated as previously described [21]. HBs, ccRCCs
and the human renal cancer cell line 786-O cells (ATCC®
CRL-1932™) were all cultured in RPMI supplemented with
20% Fetal Bovine Serum (FBS), 2mML-glutamine, and
100U/mL penicillin/streptomycin (all from GIBCO, Grand
Island, NY, USA). All the cellular assays were performed at
37 °C, 5% CO2 and ~ 95% humidity.
Transfection
Cell transfection assays were performed using Lipofecta-
mine® RNAi MAX Reagent (Thermo Scientific, Rockford,
IL, USA), following manufacturer instructions. The fol-
lowing siRNAs were used: Scrambled (#SIC001) from
Sigma-Aldrich (Saint Louis, MO, USA) for control, and a
combination of 1-CLN5 (#8149), 2-CLN5 (#18061) and 3-
CLN5 (#146678) from Ambion/Thermo Scientific for
CLN5 silencing. The transfection efficiency was around
75%, as estimated by experiments with fluorescent probes
conducted in parallel.
Cell viability assay
The viability of the ccRCC primary cultures and 786-O
cell line was measured by the “Luminescent Cell Viability
Assay” (Promega, Madison, WI, USA). This is a homoge-
neous quantitative method to determine the number of
viable cells in culture based on quantitation of the ATP
presence, which indicates metabolically active cells. Cells
were lysed at 48 h or 72 h after transfection as follows: Cell
Titer-Glo reagent (Lysis buffer, Ultra-Glo Recombinant
Luciferase, Luciferine, and Mg2+) was added to wells to a
final proportion of 1:1, and gently mixed for 30min at
room temperature (RT). Next, luminescence was mea-
sured in three independent measurements using a Glomax
Multidetection System (Promega).
Real-time RT-PCR (qPCR)
Total RNA was extracted from HB cells using Nucleo
Spin RNA kit (Macherey-Nagel, Düren, Germany). One
microgram of total RNA was reverse-transcribed in a
final volume of 20 μl with the First Strand cDNA Syn-
thesis Kit (Roche, Mannheim, Germany) using random
primers. SYBR Green PCR system (BioRad, Hercules,
CA, USA) was used to carry out real-time PCR with an
iQ5 system (BioRad). Primers used for qPCR are: 18S
Fwd: 5′-CTCAACACGGGAAACCTCAC- 3′, 18S Rev.:
5′-CGCTCCACCAACTAAGAACG-3′; BAX Fwd: 5′-
CACTCCCGCCACAAAGAT-3′, BAX Rev.: 5′-CAA-
GACCAGGGTGGTTGG-3′; CLN5 Fwd: 5′-AAGCCC
CAGTATGGGAATT-3′, CLN5 Rev.: 5′-TGCCAG
TTAATGTACTTCTGAATCC-3′.
Western blot
For protein extraction, cells were lysed on ice for 30min in
TNE buffer (50mM Tris, 150mM NaCl, 1mM EDTA, and
0.5% Triton X100) supplemented with wide-range protease
inhibitors (Roche, Basel, Switzerland) and lactacystin
(Sigma-Aldrich), a specific proteasome inhibitor. Lysates
were centrifuged at 14,000×g for 5min. Similar amounts of
protein from cleared cell lysates were boiled in SDS sample
buffer and analyzed by 4–20% SDS-PAGE under non-
reducing conditions (BioRad). Proteins from gels were
electro-transferred to nitrocellulose membranes (Amersham,
Little Chalfont, UK) followed by immunodetection with
anti-CLN5 (Abnova, Taiwan), and anti-actin (Sigma-Al-
drich). Following primary antibody incubation overnight at
4 °C, samples were washed and incubated with the corre-
sponding horseradish peroxidase-conjugated secondary anti-
bodies from Dako (Glostrup, Denmark) at RT for 1 h. All
antibodies were used at the dilution recommended by the
manufacturer. Membranes were developed by chemilumin-
escence (SuperSignal West Pico Chemiluminescent Sub-
strate, Thermo Scientific).
Statistical analysis
Results are presented as mean ± SEM. Statistical analyses
were performed using the Student’s t-test, comparing
siCLN5 results to groups Control and SiScl, independ-
ently. Statistical significance was defined when p < 0.05
(*p < 0.05; **p < 0.01, ***p < 0.001).
Abbreviations
BOECs: Blood Outgrowth Endothelial Cells; ccRCC: Clear cell Renal Cell
Carcinomas; CLN or NCL: Neuronal Ceroid Lipofuscinosis; FBS: Fetal Bovine
Serum; HB: Hemangioblastoma; HIF: Hypoxia inducible factor;
HUVECs: Human Umbilical Vein Endothelial Cells; MRI: Magnetic Resonance
Imaging; qPCR: Quantitative Polymerase Chain Reaction; VHL: Von Hippel
Lindau
Acknowledgements
We thank the family presented for their participation in this study and
providing the details needed to put together this manuscript, the Spanish
VHL patient Alliance, and Dr. Martínez-Piñeiro (MD) and Dr. Aguirre (MD) for
providing with ccRCC and HB samples respectively. We also thank Dr. Villar
Gómez de las Heras (MD) for critically reviewing the manuscript. We
acknowledge support of the publication fee by the CSIC Open Access
Publication Support Initiative through its Unit of Information Resources for
Research (URICI).
de Rojas-P et al. Orphanet Journal of Rare Diseases          (2020) 15:132 Page 5 of 6
Authors’ contributions
L.M.B. designed the complete study. L.M.B., I.R.-P., A.M.C., and V.A. wrote the
main manuscript text and figures. All experiments were done by I.R.-P, with
technical support of L.R.-P and A.R.R. A.M.C. provided blood samples. All
authors critically reviewed the manuscript and approved the final manuscript
as submitted and agree to be accountable for all aspects of the work.
Funding
Funding was provided by the projects SAF 2014–52374-R and SAF2017–
83351-R from the Ministry of Economy and Competitivity to LMB. The group
is part of the CIBER Spanish consortium for Rare Diseases, CIBERER, unit 707,
and was also financially supported by the Spanish VHL patient Alliance.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Ethics approval and consent to participate
All methods described in the present manuscript were carried out in
accordance with all the international relevant guidelines and regulations of
obliged fulfilment in the National Research Council of Spain (CSIC), and in
agreement with worldwide regulations for Molecular Research, as also
following the guidelines of the Declaration of Helsinki. A written informed
consent was obtained from the patients prior to sample collection and
publication of this case report.
Consent for publication
All authors critically reviewed the manuscript and approved the final
manuscript as submitted and agree to be accountable for all aspects of the
work.
Competing interests
The authors declare no competing interests.
Received: 5 December 2019 Accepted: 18 May 2020
References
1. 2014 Report on the State of the Art of Rare Disease Activities in Europe.
EUCERD Joint Action. European Comission. 2019. http://ec.europa.eu/health/
rare_diseases/. Accessed 10 Oct 2019.
2. Genetic and Rare Diseases Information Center. NIH, Gaithersburg, MD. 2019.
http://rarediseases.info.nih.gov/. Accessed 10 Oct 2019.
3. Rare diseases in numbers: preliminary report from an on going
bibliographic study initiated by Eurordis in partnership with Orphanet.
Orphanet Rare Disease Platform, Paris. 2018. https://www.orpha.net/
actor/Orphanews/2005/doc/Rare_Diseases_in_Numbers.pdf. Accessed
10 Oct 2019.
4. What Is a Rare Disease? EURORDIS Rare Diseases Europe. Fondation
Universitaire, Brussels. 2007. https://www.eurordis.org/content/what-rare-
disease. Accessed 10 Oct 2019.
5. Fanny Cortés DM. Las Enfermedades Raras Rare Diseases. Clínica Las
Condes. 2015;26:425–31.
6. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, Thomson D,
Terry SF, de Montleau B, Ardigò D, Hivert V, Boycott KM, Baynam G, et al.
Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin
Transl Sci. 2018;11:21–7.
7. Lal D, Neubauer BA, Toliat MR, Altmöller J, Thiele H, Nörnberg P,
Kamrath C, Schänzer A, Sander T, Hahn A, Nothnagel M. Increased
probability of co-occurrence of two rare diseases in consanguineous
families and resolution of a complex phenotype by next generation
sequencing. PLoS One. 2016;11:1–16.
8. Rider JA, Rider DL. Batten disease: past, present, and future. Am J Med
Genet Suppl. 1988;5:21–6.
9. Radke J, Stenzel W, Goebel HH. Human NCL neuropathology. Biochim
Biophys Acta - Mol Basis Dis. 1852;2015:2262–6.
10. Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (batten
disease). Biochim Biophys Acta - Mol Basis Dis. 1852;2015:2237–41.
11. Barontini M, Dahia PLM. VHL disease. Best Pract Res Clin Endocrinol Metab.
2010;24:401–13.
12. Maher ER, Neumann HPH, Richard S. Von Hippel-Lindau disease: a clinical
and scientific review. Eur J Hum Genet. 2011;19:617–23.
13. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F,
Affara NA, Maher ER. Somatic inactivation of the VHL gene in Von Hippel-
Lindau disease tumors. Am J Hum Genet. 1997;60:765–71.
14. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev
Cancer. 2002;2:673–82.
15. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin
Oncol. 2004;22:4991–5004.
16. Poulsen MLM, Budtz-Jørgensen E, Bisgaard ML. Surveillance in von Hippel-
Lindau disease (vHL). Clin Genet. 2010;77:49–59.
17. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Moore AT, Ferguson-
Smith MA. Clinical features and natural history of von hippel-Lindau disease.
Qjm. 1990;77:1151–63.
18. Maher ER, Iselius L, ML JRWY, Benjamin C, Harris R, AW JS, NM MAF-S. Von
Hippel-Lindau disease: a genetic study. J Med Genet. 1991;28:443–7.
19. Basu A, Haldar S. The relationship between BcI2, Bax and p53:
consequences for cell cycle progression and cell death. Mol Hum Reprod.
1998;4:1099–109.
20. Gascón A, Escobar B, Montero-Conde C, Rodríguez-Antona C, Ruiz-Llorente
S, Osorio A, et al. Loss of the actin regulator HSPC300 results in clear cell
renal cell carcinoma protection in Von Hippel-Lindau patients. Hum Mutat.
2007;28(6):613–21.
21. Albiñana V. Villar Gómez De Las Heras K, Serrano-Heras G, Segura T, Perona-
Moratalla AB, Mota-Pérez M, De Campos JM, Botella LM. Propranolol
reduces viability and induces apoptosis in hemangioblastoma cells from
von Hippel-Lindau patients. Orphanet J Rare Dis. 2015;10:1–12.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
de Rojas-P et al. Orphanet Journal of Rare Diseases          (2020) 15:132 Page 6 of 6
